GENE LOGIC ENTERS INTO AGREEMENT WITH LILLY TO DISCOVER NEW DEVELOPMENT PATHS FOR MULTIPLE CLINICAL DRUG CANDIDATES

Gene Logic Inc. announced that it has entered into a drug repositioning and development agreement with Eli Lilly and Company to seek alternative development paths for multiple Lilly drug candidates. All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety. Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=6852115)